Joseph A. Tami

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 748 citations

Medicine, Pharmacology, Clinical Pharmacology +6

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

Bruce Yacyshyn, Mary Beth Bowen-Yacyshyn, Lawrence D. Jewell et al. · Gastroenterology · 1998 · 386 citations · Full text

Veterinary Medicine, Clinical Sciences, Immunology +14

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Jean‐Claude Tardif, Ewa Karwatowska‐Prokopczuk, Eric St Amour et al. · European Heart Journal · 2021 · 202 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α

K. Lea Sewell, Richard S. Geary, Brenda F. Baker et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 120 citations

Life Sciences, Immunology, Pharmacology +10

Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study

Elif A Oral, Abhimanyu Garg, Joseph A. Tami et al. · Journal of clinical lipidology · 2022 · 69 citations

Medicine, Endocrinology, Pharmacotherapy +11